You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Biogen reported Q3 2026 revenue of $2.8 billion, up 11% year-over-year, and raised the lower end of 2026 non-GAAP diluted EPS guidance to between $12.20 and $13.00. It expects at least $250 million of run rate synergies by the end of 2027.
Biogen completed its Apellis acquisition on May 14, 2026, adding SYFOVRE and EMPAVELI; third-quarter total revenue rose $269.4 million, or 10.6%, while total cost and expense rose $835.7 million, or 42.3%.
Biogen reported third-quarter 2026 revenue of $2.8 billion, up 11% year-over-year, GAAP diluted EPS of $(0.14), and Non-GAAP diluted EPS of $2.62. It raised the lower end of full-year Non-GAAP diluted EPS guidance to $12.20 to $13.00 from $12.00 to $13.00.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Biogen reported Q2 total revenue of $2.7B, up 3% YoY, and raised full-year 2026 total revenue guidance from a mid-single-digit percentage decrease to a mid-single-digit percentage increase, while updating its full-year non-GAAP diluted EPS range to $12–$13.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Biogen's share of the Denali collaboration development expense reflected in research and develop | $3.3M | three months ended June 30, 2026 filing | — |
| Biogen's share of the LEQEMBI Collaboration development expense reflected in research and develo | $30.8M | three months ended June 30, 2026 filing | — |
| Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, ge | $77.6M | three months ended June 30, 2026 filing | — |
| Biogen's share of the Stoke collaboration development expense reflected in research and developm | $4.3M | three months ended June 30, 2026 filing | — |
| Biogen's share of the Supernus collaboration development expense reflected in research and devel | $0.6M | three months ended June 30, 2026 filing | — |
| Biogen's share of the Supernus collaboration sales and marketing expense reflected in selling, g | $26.7M | three months ended June 30, 2026 filing | — |
| Biogen's share of the UCB collaboration development expense reflected in research and developmen | $14.6M | three months ended June 30, 2026 filing | — |
| received from Royalty Pharma | $25M | the three months ended June 30, 2026 filing | — |
| reserves for discounts and allowances as a percentage of gross product revenue | 30.7% | the three months ended June 30, 2026 filing | — |
| Total Denali collaboration development expense | $5.5M | three months ended June 30, 2026 filing | — |
| Total development expense incurred by the collaboration related to the advancement of LEQEMBI | $61.5M | three months ended June 30, 2026 filing | — |
| Total sales and marketing expense incurred by the LEQEMBI Collaboration | $155.2M | three months ended June 30, 2026 filing | — |
| Total sales and marketing expense incurred by the Supernus collaboration | $53.3M | three months ended June 30, 2026 filing | — |
| Total Stoke collaboration development expense | $14.3M | three months ended June 30, 2026 filing | — |
| Total Supernus collaboration development expense | $1.2M | three months ended June 30, 2026 filing | — |
| Total UCB collaboration development expense | $29.3M | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIIB
this stock
Biogen Inc.
|
$37.46B | +44.0% | +2.2% | — | 3.7% |
|
LLY
ELI LILLY & Co
|
$1.36T | +34.3% | +44.7% | 46.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$687.89B | +38.1% | +6.0% | 43.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$521.50B | +29.1% | +8.6% | 50.8 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$364.26B | +40.4% | +1.3% | 152.3 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Biogen completed its Apellis acquisition on May 14, 2026, adding SYFOVRE and EMPAVELI; third-quarter total revenue rose $269.4 million, or 10.6%, while total cost and expense rose $835.7 million, or 42.3%.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIIB | +2.0% | +8.9% | +31.2% | -0.1% | +44.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -0.6% | +10.1% | +30.7% | +0.1% | +33.4% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
